Organizations bite back on MU reimbursement penalties

The latest--and low--numbers of successful Meaningful Use (MU) Stage 2 attestations, and therefore the number of providers now facing reimbursement penalties, have set up a firestorm of criticism from various professional associations.

The Centers for Medicare & Medicaid Services announced last week that about 257,000 Medicare eligible professionals (EPs) will be hit with penalties for failing to meet MU requirements. Oct. 1 was the date by which EPs had to demonstrate MU to avoid the penalty. The agency said those affected soon would receive letters about the penalty.

The American Medical Association (AMA) and the American Hospital Association (AHA) issued scathing criticism in response to the news.

"The American Medical Association is appalled by the news from [CMS] ... the Meaningful Use program was intended to increase physician use of technology to help improve care and efficiency," AMA President-Elect Steven Stack, MD, said in a statement. "Unfortunately, the strict set of one-size-fits-all requirements is failing physicians and their patients."

"These widespread physician penalties reflect the many challenges providers face with the Meaningful Use program," Chantal Worzala, MD, PhD, AHA's director of policy, said in a statement. "Hospitals cannot be successful without their physician partners. It is time for CMS to address providers' concerns about the program."

The penalty is the result of failure to meet MU Stage 2 but CMS announced the low attestation numbers last month. As of Nov. 1, 43,898 eligible professionals and 1,903 eligible hospitals attested for the 2014 reporting period, although the program has more than 500,000 active registrants.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.